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While CD8+ T cells specific for human cytomegalovirus (HCMV) have been
extensively studied in both healthy HCMV seropositive carriers and patients undergoing
immunosuppression, studies on the CD4+ T cell response to HCMV had lagged
behind. However, over the last few years there has been a significant advance in our
understanding of the importance and contribution that CMV-specific CD4+ T cells make,
not only to anti-viral immunity but also in the potential maintenance of latently infected
cells. During primary infection with HCMV in adults, CD4+ T cells are important for
the resolution of symptomatic disease, while persistent shedding of HCMV into urine
and saliva is associated with a lack of HCMV specific CD4+ T cell response in young
children. In immunosuppressed solid organ transplant recipients, a delayed appearance
of HCMV-specific CD4+ T cells is associated with prolonged viremia and more severe
clinical disease, while in haematopoietic stem cell transplant recipients, it has been
suggested that HCMV-specific CD4+ T cells are required for HCMV-specific CD8+
T cells to exert their anti-viral effects. In addition, adoptive T-cell immunotherapy in
transplant patients has shown that the presence of HCMV-specific CD4+ T cells is
required for the maintenance of HCMV-specific CD8+ T cells. HCMV is a paradigm
for immune evasion. The presence of viral genes that down-regulate MHC class II
molecules and the expression of viral IL-10 both limit antigen presentation to CD4+ T
cells, underlining the important role that this T cell subset has in antiviral immunity. This
reviewwill discuss the antigen specificity, effector function, phenotype and direct anti-viral
properties of HCMV specific CD4+ T cells, as well as reviewing our understanding of
the importance of this T cell subset in primary infection and long-term carriage in healthy
individuals. In addition, their role and importance in congenital HCMV infection and during
immunosuppression in both solid organ and haemopoietic stem cell transplantation
is considered.
Keywords: human cytomegalovirus (HCMV), CD4+ T cell, solid organ transplant (SOT), hematopoietic stem cell
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INTRODUCTION
Over the last few decades research in both humans and murine models has clearly demonstrated
that both the innate and adaptive branches of the immune response play a role in resolving
both primary, reactivating and super-infections with cytomegalovirus (CMV). In particular,
studies in transplantation patients (Sester et al., 2001; Einsele et al., 2002; Peggs et al.,
2003; Gratama et al., 2008) and in adults with primary human CMV (HCMV) infections
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(Rentenaar et al., 2000; Gamadia et al., 2003; Lilleri et al.,
2008b) have confirmed the vital role that HCMV specific
CD4+ T cells play in controlling symptomatic disease.
Here, we present a detailed overview of the evidence from
many studies of the specific and direct anti-viral role that
CD4+ T cells play in HCMV infections in the healthy and
immunocompromised patients. In particular, we focus on
the importance of both understanding and assessing the full
functionality of CMV specific CD4+ T cells responses in patients
to minimize the burden of CMV infection in transplantation and
congenital infections.
CD4+ T Cells, Their Activation and Role in
Adaptive Immunity
CD4+ T cells are an important and multifaceted component of
the adaptive immune response to viruses and other pathogens. In
healthy adults, CD4+ T cells typically comprise the majority of
T cells present. However, cytomegalovirus infection can lead to
perturbation of the composition of circulating T cell populations
(Chidrawar et al., 2009; Wertheimer et al., 2014). CD4 is a
co-receptor that binds the Major Histocompatibility Complex
(MHC) Class II molecules on antigen presenting cells (APC) that
present peptides to the TCR present on the T cell (Glatzova and
Cebecauer, 2019). MHC class II molecules comprise an α and
β chain heterodimer which, when assembled, provide a peptide-
binding cleft in which antigen is presented. In humans three gene
loci encode the MHC class II molecules—HLA-DR, -DQ, and
DP (Blum et al., 2013)—allowing for a wide diversity of peptides
to be presented. MHC class II molecules are synthesized in the
endoplasmic reticulum (ER) and transported to endosomes with
an invariant chain present to stabilize the structure via the Golgi
apparatus. Peptides generated by proteolysis of endocytosed
proteins are exchanged for the fragment, Class II–associated
Invariant Peptide (CLIP), which remains in the peptide binding
cleft of the assembled MHC class II molecule within late
endosomes. The loaded complex is then transported to the cell
surface (Blum et al., 2013), hence allowing CD4+ T cells to
recognize exogenously-derived proteins.
Interaction of CD4+ T cells with MHC class II complexes
on APCs results in formation of a complex known as an
immunological synapse which precedes T cell activation. The
formation of the synapse allows the clustering of various co-
stimulatory molecules, including CD28 and CD40L, which
are expressed by the T cell and are required for successful
intracellular signaling and subsequent activation of the CD4+
T cell (Glatzova and Cebecauer, 2019). Following activation, the
CD4+ T cell population expands and then typically contracts
before establishing a memory population. The generation of
long lived antigen specific memory CD4+ T cells involves the
integration of multiple cellular and cytokine processes (Kara
et al., 2014; Nguyen et al., 2019). CD4+ memory T cells can
be subdivided into a number of different functional subsets
(Figure 1), which includes T helper 1 (Th1) and T regulatory
(Treg) cellular types. The generation of the different subsets is
a result of the location of the CD4+ T cell, the local cytokine
environment, and expression of cellular transcription factors.
For example, differentiation into the Th1 subset, which is
characterized by production of anti-viral cytokines such as IFN-
γ, is as a result of exposure to IL-12, IFN-γ, and expression of
the transcription factor T-bet (Zhu et al., 2010; Nguyen et al.,
2019). CD4+ T cell memory and effector populations can also
be defined according to their differentiation status, which is
indicated by the expression or loss of expression of various
cell surface markers. Common memory subsets include central
memory (TCM), effector memory (TEM), CD45RA re-expressing
effector memory cells (TEMRA) and Tissue resident memory
(TRM) subsets (Nguyen et al., 2019). CMV-specific CD4+ T
memory recall cell responses have typically been shown to be of
a differentiated memory cell phenotype, where downregulation
of co-stimulatory molecules CD27 and CD28 and expression of
CD57 and re-expression of CD45RA are observed (van Leeuwen
et al., 2004; Weekes et al., 2004; Fletcher et al., 2005; Casazza
et al., 2006; Lilleri et al., 2008b; Libri et al., 2011; Dirks et al.,
2013). Memory CD4+ T cell populations also express chemokine
receptors and integrin-related proteins, which allow homing to
specific tissue sites (Nguyen et al., 2019). For instance, CMV-
specific memory CD4+ T cells have been shown to express
CX3CR1, enabling homing of these cells to activated vascular
endothelium (Pachnio et al., 2016).
CD4+ T Cells and Anti-viral Immunity
The roles that CD4+ T cells fulfill in anti-viral immune responses
can broadly be divided into 3 categories: recruitment of lymphoid
cells to sites of infection, mediating expansion or function of
other effector cells, or providing direct anti-viral effects through
cytokine production or cell-mediated cytotoxicity. The classic
view of CD4+ T cells is as a helper cell. In anti-viral responses
they help recruit CD8+ T cells to sites of infection by promoting
engagement of CD8+ T cells with dendritic cells via chemokines
such as CCL3 and CCL4. They can also facilitate entry of naïve
CD8+ T and B cells to draining lymph nodes and recruit
innate or antigen-specific effectors to sites of viral replication
via production of IFN-γ and local chemokine secretion. CD4+
T cells can also mediate expansion and function of both B
cells and CD8+ T cells. Binding of antigen on CD4+ T cells
initiates expression of CD40L, which engages CD40 on B cells
and induces proliferation and differentiation of B cells, initially
in extra-follicular foci and then in germinal centers of lymph
nodes, resulting in production of antibody-producing plasma
cells and memory B cells. With CD8+ T cells, CD4+ T cells
have been shown to facilitate development of memory CD8+ T
cells via various mechanisms, such as through downregulation
of TNF-related apoptosis-inducing ligand (TRAIL) expression,
generation of cytokines such as IL-2, or direct ligation of CD40
on naïve CD8+ T cells by CD40L on CD4+ T cells (Sant and
McMichael, 2012; Swain et al., 2012).
Finally, there has been increasing evidence of a role of
CD4+ T cells in antiviral immunity that is independent of their
helper function through two distinct mechanisms: production of
cytokines IFN-γ and TNF, and through direct cytolytic actions
via perforin- and Fas-dependent killing (Juno et al., 2017).
In particular, these cytotoxic T cells have been described to
emerge after CMV infection (van Leeuwen et al., 2004) and
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FIGURE 1 | CD4+ T cell subsets and associated transcription factors and cytokines. Following activation of the CD4+ T cell cytokines present in the
microenvironment (indicated on arrows) determine the type of effector cell that is induced by triggering expression of particular transcription factors (labeled in each
cell subset). The typical cytokines secreted by each CD4+ T cell subset are also shown. Mature Th1 cells produce IFN-γ which can upregulate MHC Class I and II
molecules on cells in the local microenvironment and the cells are anti-viral and protective against intracellular bacteria and fungi. Whereas, Th2 cells typically secrete
IL-4, IL-5, and IL-13 and are active against extracellular parasites and implicated in allergy responses. Th9 cells are important in mediating anti-parasite immune
responses, secreted IL-9 activates mast cells and increases basophil and eosinophil functions. T follicular helper cells (Tfh) are specialized to provide B cell help and
assist in germinal center formation, mature Th17 cells aid in protection against extracellular bacteria and fungi. Treg cells are characterized by the expression of the
transcription factor Foxp3 and help to control activation of the immune response, however Th22 cells have been shown to play a role in mediating immune responses
in the skin.
have demonstrated a capability to lyse CMV antigen-expressing
target cells in vitro (van Leeuwen et al., 2006). The majority
of CD4+ T cells produced in response to viral infection are
of the T-helper 1 subtype, producing IFN-γ and expressing the
transcription factor T-bet (Caza and Landas, 2015). This has
also been observed following primary CMV infection (Rentenaar
et al., 2000). However, other functional subsets are also involved
in anti-viral immunity. T follicular helper cells, characterized
by their expression of the chemokine receptor CXCR5 and
transcriptional repressor Bcl6, produce IL-21 which facilitates
germinal center B cell selection and differentiation of activated
B cells that provide long-term antibody-mediated protection
against viral pathogens (Hale et al., 2013; Hale and Ahmed, 2015).
Regulatory T cells (Tregs), identified by expression of Foxp3 and
CD25 on their cell surface, limit immunopathology in chronic
viral infections (Karkhah et al., 2018). Tregs that develop in the
thymus are termed natural Tregs, while those that develop in
peripheral lymphoid organs are termed inducible Tregs (iTregs).
In the context of anti-viral responses to CMV, CMV-specific
iTregs were found to be increased in older women and may
attenuate the chronic vascular injury caused by CMV (Terrazzini
et al., 2014).
The Role of CD4+ T Cells Against HCMV
Infection in the Healthy
Primary HCMV infection in the immunocompetent host is
usually asymptomatic and may manifest as a viral syndrome,
occasionally accompanied by end-organ involvement—
commonly hepatomegaly, splenomegaly and lymphadenopathy.
In immunocompetent individuals, the innate and adaptive
arms of the immune system are capable of limiting lytic
viral replication and preventing end-organ disease (Crough
and Khanna, 2009) resulting in a largely self-resolving
mononucleosis-like illness, although the virus then establishes
a lifelong persistent infection through latency with periods of
reactivation, during which productive lytic infection occurs
(Sinclair and Poole, 2014). Rarely, HCMV infection in adults
with effective immune responses does cause severe disease. The
immune response in these individuals are typically characterized
by large expansions of NK cell and T cell populations, particularly
CMV-specific CD8+ T cells (Riou et al., 2017). CMV-specific
CD8+ T cell populations have been studied extensively and are
an essential component of effective immune control of CMV
infection, as studies in transplant patients have clearly shown
that recovery of the CMV specific CD8+ T cell response is
crucial to successful protection against CMV disease (Tormo
et al., 2010a,b, 2011). Indeed, the earliest studies investigating
the effectiveness of adoptive T cell transfer therapy revealed
that patients receiving ex vivo expanded CMV specific CD8+ T
cells are protected from both primary and reactivating infection
(Riddell et al., 1992; Walter et al., 1995; Einsele et al., 2002; Peggs
et al., 2003). In healthy HCMV sero-positive adults there has
been found to be a high frequency of CMV-specific memory
T cell populations, with epitopes derived from pp65 and IE1
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regularly reaching 5–10% of total CD8+ T cells in peripheral
blood (Khan et al., 2002a,b; Sylwester et al., 2005). Another
characteristic of the expanded CMV specific memory CD8+
T cell populations is their highly differentiated phenotype,
including a large proportion of cytotoxic effector memory cells
which have re-expressed CD45RA (Jackson et al., 2011, 2014).
Originally the role of CD4+ T cells in mounting anti-CMV
responses was presumed to be a supportive one, enhancing
CD8+T cell responses to the virus (Tormo et al., 2011). However,
multiple studies in transplant settings and infants infected with
CMV show that poorer CD4+ T cell responses result in a
prolonged course of viral shedding and more severe disease
(Sester et al., 2001; Einsele et al., 2002; Peggs et al., 2003; Tu
et al., 2004; Gratama et al., 2008). Studies of the role of CMV-
specific CD4+ T cells during acute CMV infection in healthy
adults have mainly been conducted in pregnant women cohorts,
these have revealed that at early time points post infection
responses to gB and pp65 CMV proteins are the dominant
responses (Mele et al., 2017). However, the frequency of CMV
specific CD4+ T cells to primary infection are lower compared
to memory responses (Antoine et al., 2012; Fornara et al., 2016,
2017; Mele et al., 2017), responding CD4+ T cells have lower
functional avidity (Antoine et al., 2012) and express higher
levels of immune checkpoint proteins such as PD-1 compared
to CMV specific CD4+ T cell memory responses (Antoine
et al., 2012; Mele et al., 2017; Riou et al., 2017). Whereas, recall
memory CD4+ T cell populations in CMV seropositive donors
are characterized by expanded highly specific effector memory
populations (Bitmansour et al., 2002) with multiple functions
(Casazza et al., 2006). Although the frequency of CMV specific
CD4+ T cell memory responses are expanded compared to those
established at the time of infection, there is very little evidence
of continual accumulation, so called “memory inflation,” of
CMV specific CD4+ T cells over time in humans (reviewed in
Jackson et al., 2019).
HCMV Antigen Specificity of CD4+ T Cells
Initially, studies to identify HCMV-specific CD4+ T cells used
lysate derived from HCMV infected fibroblast cells to stimulate
the antigen-specific response (Lindsley et al., 1986; Sester et al.,
2002; Pourgheysari et al., 2007, 2009). Subsequently, studies of
the CD8+ T cell repertoire identified multiple peptides that
were most frequently recognized by HCMV-specific CD8+ T
cells (Kern et al., 1999; Wills et al., 2002; Elkington et al., 2003;
Gibson et al., 2004). Among themost commonly recognized were
pp65 and IE-1, although some structural, early/late antigens, and
HCMV-encoded immunomodulators were also identified (such
as pp28, pp50, gH, gB, US2, US3, US6, and UL18) (Elkington
et al., 2003). This was also used to guide studies identifying CD4+
T cells that were HCMV-specific (Weekes et al., 2004). An in
depth study of T cell responses to 213 HCMV open reading
frames (ORFs) found that CD4+ T cells recognize proteins
from up to 125 different ORFs. In particular, CD4+ T cells
recognized immediate-early (IE) gene products by 2.3-fold over
their representation in the HCMV genome, and there was also
preferential recognition of primary immune evasion proteins
and viral tegument and glycoproteins (Sylwester et al., 2005).
Recognition of HCMV glycoproteins by CD4+ T cells has also
been reported in a number of other studies (Crompton et al.,
2008; Pachnio et al., 2015, 2016).
Measurement of the functional capability of these cells has
also evolved. Most studies have measured intracellular cytokine
production, predominantly IFN-γ, to determine if the CD4+ T
cells were specific for HCMV (reviewed in Jackson et al., 2011).
More recently, work has demonstrated a functional capability of
these cells in vitro, where autologous HCMV-specific CD4+ T
cells (identified by upregulation of activationmarkers CD40L and
4-1BB above the background response) were shown to be able to
restrict viral dissemination in monocyte-derived dendritic cells
(Jackson et al., 2017). In addition, CD4+ T cells from a cohort of
healthy seropositive donors were also found to recognize latency-
associated viral genes UL138 and LUNA (latency-associated
unidentified nuclear antigen), and the T-cell response to these
antigens included secretion of cIL-10, an immunosuppressive
cytokine that may function to suppress anti-viral immune
responses (Mason et al., 2013). Suppressive CMV-specific CD4+
T cells that secrete IL-10 or have a phenotype of a regulatory
cell (Treg) have been identified in other studies (Tovar-Salazar
et al., 2010; Schwele et al., 2012; Terrazzini et al., 2014; Clement
et al., 2016) and these cells likely play an important role in
controlling the immune response to CMV in reactivating disease
in particular. Follicular helper T cells (Tfh) that are CMV-specific
for the glycoprotein pentameric complex (gH/gL/pUL128L)
increase in numbers during the early phase of infection resulting
in a rise in neutralizing antibodies, once the virus is cleared Tfh
numbers decrease but glycoprotein specific Tfh CD4+ T cells
are maintained over time (Bruno et al., 2016). CMV-specific
CD4+ T cells, identified either by upregulation of activation
markers or usingMHC class II tetramers, have also been shown to
have cytotoxic capacity, measured via surrogate markers such as
expression of CD107a (a marker of degranulation), detection of
intracellular perforin and granzyme molecules or via cytotoxicity
assays including chromium release assays (Gamadia et al., 2004;
van Leeuwen et al., 2004, 2006; Crompton et al., 2008; Mason
et al., 2013; Pachnio et al., 2015, 2016; Jackson et al., 2017). This
suggests that CMV-specific CD4+ T cells have the ability to kill
CMV infected cells.
HCMV Immune Evasion of CD4+ T Cell
Responses
The HCMV genome encodes multiple evasion proteins during
the course of infection that allows the virus to modulate
intrinsic, innate and adaptive immune responses (Wills et al.,
2015), the end result of this being the persistence of active
primary infection viremia even in the immunocompetent host,
which is accompanied by virus excretion for months (in adults)
or even years (in children). Of particular relevance to this
review of CD4+ T cell responses to HCMV is the observation
that persistent shedding of virus into urine and saliva is
associated with a lack of CD4+ T cell response in healthy
children (Tu et al., 2004).
Evasion via Downregulation of MHC Class II Proteins
by US2 and US3
Early work characterizing essential and non-essential genes of
HCMV found that infection led to downregulation of MHC
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class I molecules on the surface of infected cells (Barnes and
Grundy, 1992; del Val et al., 1992; Beersma et al., 1993; Gilbert
et al., 1993; Yamashita et al., 1993). The US1-US11 region of
the HCMV genome encodes at least 4 proteins, US2, US3, US6,
and US11 that can independently interfere with the stability,
assembly or export of MHC class I and II molecules (Johnson
and Hill, 1998; Ploegh, 1998). US2 has been shown to affect
the MHC class II processing pathway, specifically by binding
to MHC class II-α chains and assembled MHC class II-α/β/Ii
complexes, leading to their degradation (Tomazin et al., 1999).
US3 alters assembly of MHC class II complexes by binding
HLA-DR (but not HLA-DM) proteins before or during assembly
of α/β complexes in the ER, preventing the binding of the
invariant chain. This leads to mislocalization of these complexes
to other post-Golgi compartments and results in the reduction of
antigen presentation in US3-expressing cells (Hegde et al., 2002)
(Figure 2).
Evasion via Downregulation of Class II Transcriptional
Activator and Modulating the Effects of IFN-γ
Interferon-γ (IFN-γ) upregulates MHC class II molecules in cells
constitutively expressing MHC class II, such as B cells, dendritic
cells, and professional antigen presenting cells (APCs). However,
it is also able to induce MHC class II expression in cells that do
not constitutively express MHC class II, such as epithelial cells
and fibroblasts, via the MHC class II transactivator gene (CIITA)
(Steimle et al., 1994). The mechanism of how this occurs is not
fully elucidated, however it involves regulation of a number of
signaling pathways and transcription factors in a cell specific
manner. Binding of IFN-γ to its cell-surface receptor activates
the protein tyrosine kinases Jak1 and Jak2, and activation of
these Jak kinases phosphorylates the tyrosines of the cytoplasmic
transcription factor Stat1, and translocates it to the nucleus. Stat1
then binds directly to the IFN-γ-activation site (GAS) element of
CIITA. The CIITA promoter region also includes an interferon
regulatory factor (IRF)-1 binding site and binding of both these
regions are essential for activation by IFN-γ (Muhlethaler-Mottet
et al., 1998). Activation of CIITA leads to the assembly of a
MHC class II enhanceosome, triggering a cascade of events that
ends in autophosphorylation of CIITA and allows transcription
of MHC class II genes to initiate (Devaiah and Singer, 2013).
In macrophages the transcription factor NFAT5 is required for
expression of the CIITA and MHC class II molecules, but this is
not the case for dendritic cells and B cells (Buxade et al., 2018).
The HCMV genome encodes for a number of proteins that
assist in modulation of the effects of IFN-γ (Goodwin et al., 2018)
and directly modulate CIITA transcription. In Langerhans cells,
a dendritic cell subset, HCMV infection results in a decrease
in constitutive expression of CIITA (Lee et al., 2011). Further
evidence in a transfected cell line model system showed that
CMV downregulates MHC class II expression on the cell surface
via regulation of CIITA and independently of known CMV Class
II modulators US2 and US3 (Cebulla et al., 2002). Recently,
it has also been shown in kasumi-3 cells, a myeloid lineage
tumor cell line, that reduction in endogenous expression of
MHC class II is as a result of decreased CIITA transcription
(Sandhu and Buchkovich, 2020). UL23 binds to the Stat effector
molecule N-myc, preventing proper activation and translocation
of the Stat1 homodimers required for IFN-γ signaling (Feng
et al., 2018), while UL31 preferentially binds the cytosolic
DNA sensor cGAS in a manner that results in inhibition of
interferon-associated gene transcription (Huang et al., 2018). The
tegument protein pp71 binds Daxx, a Death-domain associated
protein, and targets it for degradation, resulting in an inhibitory
effect on induction of downstream antiviral genes (Cantrell
and Bresnahan, 2006; Hwang and Kalejta, 2007; Lukashchuk
et al., 2008). It has also been demonstrated that pp71 can
negatively regulate the signaling role of STING (Stimulator of
Interferon Genes) by inhibiting its translocation to the nucleus
and preventing recruitment of accessory proteins to the complex
(Fu et al., 2017) (illustrated in Figure 2). The end result of all
these modulations is a decrease in transcription of downstream
interferon-γ-associated genes, which, among other effects, results
in decreased expression ofMHC class II on the surface of infected
cells and a decreased ability to present antigen via the MHC class
II antigen presentation pathway.
HCMV SPECIFIC CD4+ T CELLS
RESPONSES IN IMMUNOCOMPROMISED
AND IMMUNONAÏVE PATIENTS
As already discussed, studies in transplant patients have shown
the essential role that the CMV-specific CD4+ T cell response
plays in successful resolution of active CMV infection in this
setting. Many of these studies were performed due to the
significant morbidity and mortality caused by opportunistic
CMV infection and reactivation in immunocompromised and
immunonaïve patients. Therefore, as well as informing our
understanding of how the immune response to CMV works,
these studies have revealed much about the role of CD4+
T cell responses in specific transplantation and congenital
environments and the possible manipulation of these responses
to improve clinical outcomes.
CD4+ T Cell Responses to HCMV in Solid
Organ Transplant Recipients
Cytomegalovirus is the most common viral opportunistic
infection in solid organ transplant (SOT) recipients, with the risk
of infection or reactivation being stratified according to the CMV
sero-status of the donor and recipient. An organ donation from a
sero-positive donor to a sero-negative recipient (D+/R–) carries
the highest risk, a sero-positive recipient (R+) is at intermediate
risk, and D-/R- transplants are at lowest risk (Kowalsky et al.,
2013). Other factors affecting risk of CMV reactivation or disease
include the type of organ transplanted, with lung and small
intestine transplant recipients having the highest risk, while liver
and heart recipients are at an intermediate risk and kidney
recipients are at the lowest risk of CMV infection (Humar et al.,
2009). The reasons for this stratification are likely related to the
amount of immunosuppression required, and the latent viral
load present in these organs (Meesing and Razonable, 2018). In
addition, use of antilymphocyte antibody induction agents also
increase risk of reactivation (Preiksaitis et al., 2005).
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FIGURE 2 | HCMV encoded proteins which help to evade CD4+ T cell mediated immune responses. Illustrating the impact of US2 and US3 on the MHC Class II
protein presentation pathway and the effect of various HCMV encoded proteins on Class II Transcriptional activator (CIITA) and interferon gamma (IFN-γ) signaling
pathways and IFN-γ stimulated gene (ISG) transcription.
In 2001, it was demonstrated that in the first months after
kidney transplantation clinical symptoms of CMV disease were
preceded by a decrease in CMV-specific CD4+ T cell frequencies
(Sester et al., 2001). Subsequently it was found that significantly
lower CD4+ T cell responses (measured by IFN-γ production)
to pp65 were associated with concurrent CMV replication in
sero-positive recipients, suggesting that CMV-pp65 CD4+ T
cell responses above 0.03% in PBMCs of kidney transplant
patients under stable immunosuppression were associated with
lower risk of concurrent and future CMV replication for the
following 8 weeks (Egli et al., 2008). In liver transplant recipients,
the data is more heterogenous. A study of 17 high-risk liver
transplant patients (D+/R–) found IFN-γ production by CD4+
T cells following CMV lysate stimulation in all patients, but
no significant association between the presence of these CMV-
specific IFN-γ-producing CD4+ T cells and development of
CMV viremia in this cohort (La Rosa et al., 2007). However,
another study involving 29 liver transplant patients found that
CD4+ T cells producing IFN-γ, IL-2 or both cytokines in
response to a peptide mix containing pp65, IE1, and CMV lysate
occurred at a lower frequency in recipients who subsequently
develop viremia (Nebbia et al., 2008).
In studies involving SOT where the recipient is CMV sero-
positive the results are more consistent. A study involving 38
SOT CMV sero-positive recipients showed that patients with
a higher number of HCMV-specific CD4+ T cells detected
prior to transplantation were more likely to have earlier
immune restoration and less likely to have HCMV infections
requiring anti-viral treatment (Gerna et al., 2006). Subsequent
studies involving larger cohorts of SOT recipients have
corroborated these observations, showing that reconstitution
of HCMV–specific CD4+ and CD8+ T cell responses were
required to control infection, whereas patients who only
regained CD8+ T cell responses were not (Gerna et al.,
2011; Lilleri et al., 2018). Recently it has been shown
that a reduction in the size of CMV specific CD4+ T
cell responses measured using a diagnostic flow cytometry
test is more predictive of CMV events occurring than
the reduction in CD8+ T cells in transplantation patients
(Rogers et al., 2020).
The protective nature of the CMV specific CD4+ T cell
responses to multiple CMV proteins was tested by using CMV-
infected autologous in vitro derived dendritic cells as stimulation.
This was found to be more effective at predicting protection from
disease than using only pp65 or IE proteins as stimulus in a small
cohort of SOT patients (Lilleri et al., 2007b). This observation
is supported by more recent work in a cohort of D+/R- liver
transplant patients which compared the use of prophylactic vs.
pre-emptive anti-viral therapy. Both patients groups had similar
CD4+ T cell responses to CMV proteins pp65 and IE-1 despite
40% of the anti-viral prophylaxis group developing late stage
CMV disease (Limaye et al., 2019).
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In summary, the presence of CMV-specific CD4+ T cells is
associated with lower risk of CMV disease. However, studies
regarding the role of CD4+ T cells in SOT recipients have largely
focused on using this as a predictive tool (San-Juan et al., 2015;
Burton et al., 2018, 2019; Lilleri et al., 2018), and it is important to
consider that these studies have relied on the production of IFN-γ
by CD4+ T cells in response to peptide stimulation or virally
infected dendritic cells as predicting the effectiveness of CMV
specific CD4+ T cell responses. This disregards other potential
anti-viral functions of the CD4+ T cells, such as cytotoxic
capacity or other secreted anti-viral factors, as a predictive tool
of the likelihood of CMV disease in solid organ transplantation.
CD4+ T Cells and Haematopoietic Stem
Cell Transplantation
In haematopoietic stem cell transplant (HSCT) recipients,
the highest risk of CMV viremia and disease occurs in the
reactivation of latent infection in R+ patients due to the ablation
of their existing CMV specific T cell response. In particular, D-
/R+ recipients are at a higher risk than D+/R+ patients, as
reactivation of latent disease in the sero-positive recipient will
appear as a primary CMV infection to the naïve lymphocytes
transplanted from the sero-negative donor (Hebart and Einsele,
2004; van der Heiden et al., 2018b).
Use of CD4+ T Cell Response to Predict Risk of
HCMV Viremia or Disease and the Relationship to
End-Organ Disease
Early observational studies of haematopoietic stem cell transplant
patients focused on examining the association of absolute CD4+
T cell recovery in these patients with the risk of development of
HCMVviremia and end-organ disease, with the aim of predicting
those at risk for CMV reactivation and disease. A study of
allogeneic bone marrow transplant (BMTs) patients showed that
a decrease in the lymphocyte count to <300 cells/µl occurred
among patients who developed CMV disease, and that a decrease
of CD4+ T cells numbers to <100/µl, 49 days following BMT
was 100% predictive for the development of CMV disease in
patients. In addition, persistent CD4 lymphopenia was only
observed in patients who died of CMV disease (Einsele et al.,
1993). A subsequent study of a cohort of 71 recipients of T-
cell-depleted BMTs showed that life-threatening opportunistic
infections occurred exclusively in patients whose CD4+ counts
were <200 cells/µl and were fatal in all patients except those
receiving donor leukocyte infusions (Small et al., 1999). These
findings are also applicable for end-organ disease—a comparison
of 2 BMT recipients who developed CMV retinitis with 14
patients who did not showed that the retinitis patients had
significantly lower CD4+ T cell counts (Kuriyama et al., 2001).
Whilst the recovery of CD4+ T cell numbers post HSCT
is an important measure in understanding the role they play
in CMV disease in these patients, it is also important to
track and measure the development of HCMV-specific CD4+
T cell responses and this association with the risk of HCMV
reactivation and overt disease occurring. A study of 48 allogeneic
HSCT recipients found that patients who had developed a
CMV-specific CD4+ T cell response by 4 weeks post-transplant,
measured by IFN-γ production following stimulation with CMV
antigens, had lower peak CMV viral loads compared to patients
with negative stimulation results (Avetisyan et al., 2006). In a
pediatric allogeneic HSCT recipient cohort, the presence of 1
HCMV-specific CD4+ T-cell/µl of blood was protective against
recurrent episodes of HCMV viremia (Lilleri et al., 2006). The
same group also examined an adult allogeneic HSCT patient
cohort, finding that the same cut-off level of 1 HCMV-specific
CD4+ T-cell/µl of blood was able to identify patients who
could spontaneously control HCMV infection in the absence of
treatment (Lilleri et al., 2008a). Studies from other transplant
centers have also seen similar results in minimum numbers
of CMV-specific CD4+ T cells predictive of preventing CMV
viremia or disease (Solano et al., 2008; Pourgheysari et al., 2009;
Tormo et al., 2011).
Most studies examining the role of CD4+ T cells in HCMV
reactivation or disease in haematopoietic stem cell recipients have
not differentiated between the risk of developing HCMV viremia
vs. the development of late-stage end-organ disease. Taking this
into account, it was found that if patients were stratified into
3 groups: (i) those that could self-resolve infection, (ii) those
that responded to treatment, and (iii) those that had recurrent
infections and end-organ disease, this third group of patients had
high levels of HCMV-specific CD8+ T cells, with persistently
low levels of total CD4+ T cells and <1 cell/µl of blood of
HCMV-specific CD4+ T cells 6 months post-transplant (Gabanti
et al., 2015). However, in patients who developed late-stage
HCMV gastro-intestinal disease, 6 out of 8 patients had levels
of HCMV-specific CD4+ T cells above 1 cell/µl and had been
viral DNA negative or at very low levels for 3 to 9 months before
developing disease. This suggests that HCMV-specific CD4+ T
cells numbers did not protect against the development of late-
stage end-organ disease. It is important to note that all these
patients were receiving immunosuppressive treatment, including
low-dose steroids (methylprednisolone), at the time of diagnosis,
and 6 out of 8 had received a transplant from a seronegative
donor, which are known risk factors for CMV viremia (Gabanti
et al., 2015).
Kinetics of Recovery of HCMV-Specific CD4+ T Cell
Numbers and the Impact of Prophylaxis and Use of
G-CSF on CD4+ T Cell Recovery
It has been theorized that HCMV reactivation causes activation
of T cells, and this leads to an early expansion of T cells and
faster reconstitution of T lymphocytes. In a study of 34 pediatric
patients who underwent allogeneic BMT, the authors found that
children with HCMV reactivation had a higher probability of
reaching the 5th percentile of total CD4+ T cells of an age-
matched healthy population (de Vries et al., 2000). This was
also seen in a study of 201 adult R+ allogeneic non-T cell-
depleted peripheral blood stem cell or bone marrow transplants
(Hakki et al., 2003). CMV-specific CD4+ T cell responses, as
measured by a lymphoproliferative response to CMV lysate,
were significantly better in patients who developed breakthrough
CMV antigenemia despite ganciclovir prophylaxis, vs. those who
did not. However, a complicating factor is the use of high-dose
steroids for treatment of graft- vs.-host disease (GVHD). When
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the subgroup of patients who developed breakthrough CMV
antigenemia were analyzed, 100% of patients without GVHD
had better recovery of the CMV-specific CD4+ T cell response
compared to patients who received high-dose steroids. They thus
concluded that high-dose steroids can override this inducing
effect of breakthrough CMV antigenemia on the CMV-specific
CD4+ T cell recovery (Hakki et al., 2003).
Emergence of CMV specific CD4+ T cell responses prior
to the CD8+ T cell response has been shown, in a primary
model of infection in solid organ transplant patients, to be
associated with a lack of overt CMV disease (Rentenaar et al.,
2000, 2001; Gamadia et al., 2003, 2004). In HSCT patients
there is evidence that recovery of CD4+ T cells before CD8+
T cells may assist with priming the CD8+ T cell response
via “licensing” of dendritic cells. Dendritic cell licensing refers
to the phenomenon of upregulation of MHC class I and co-
stimulators CD80/86 on dendritic cells after antigen presentation
to CD4+ T cells via MHC class II and CD40-CD40L interactions
have occurred. In this way, dendritic cells are able to present
antigen to, and activate, CD8+ T cells, and this allows for tighter
regulation of CD8+ T cell activation (Thaiss et al., 2011). In a
study of 6 seropositive recipients of cord blood transplants, the
appearance of CMV-pp65-specific CD4+ T-helper cells preceded
an expansion of CMV-specific CD8+ T cells. When co-cultured
with CD8+ T cells alone, these pp65-specific CD4+ T cells did
not induce cytokine production by CD8+ memory T cells, but
when done so in the presence of dendritic cells loaded with pp65,
there was activation of these CD8+memory T cells (Flinsenberg
et al., 2015).
There has also been the suggestion that ganciclovir
prophylaxis delays recovery of CMV-specific CD4+ (and
CD8+) T cell responses possibly due to a decrease in viral
replication, resulting in late-onset CMV disease (Li et al., 1994).
This observation has led to the development of pre-emptive
instead of prophylactic use of anti-viral drugs in patients.
However, in a large study of 201 R+ allogeneic HSCTs (Hakki
et al., 2003), there was no significant difference on CMV-specific
CD4+ T cell recovery between patients who received prophylaxis
vs. pre-emptive treatment with ganciclovir, the authors suggest
this may be driven by subclinical reactivation of the virus
despite ganciclovir treatment. The impact of anti-viral treatment
resulting in decreased T-cell responses to HCMV stimulation
has also been observed in pediatric allogeneic-HSCT patients. A
study of 30 allogeneic-HSCT patients showed that the patients
who received anti-CMV chemotherapy because of prolonged
viremia had lower HCMV-specific CD4+ T cell numbers and
delayed and depressed lymphoproliferative responses to HCMV
stimulation (Guerin et al., 2010).
The use of peripheral blood stem cells (PBSCs) for
transplantation improves survival in patients with high-risk
hematological malignancies compared with the use of bone
marrow (BM) as a stem cell source, because PBSC products from
donors who have received G-CSF contain higher numbers of T
cells and monocytes. However, PBSC recipients saw an increased
incidence of early HCMV reactivation and delayed recovery
of HCMV-specific immune responses, with a corresponding
lower number of HCMV-specific CD4+ T cells (as measured by
limiting dilution assay and CMV-specific cell lysis) in the stem
cell product (Guerrero et al., 2012). This may be as a result of
G-CSF administration to the donor, which is given in order to
mobilize stem cells to migrate to the peripheral blood, but can
also cause the reactivation of HCMV from latency. However, a
subsequent study showed that although a reduced diversity of
the TCRβ repertoire of CD4+ T cells was significantly correlated
with HCMV (and EBV) reactivation, administration of G-CSF
did not change this repertoire (Ritter et al., 2015). A recent study
that measured the frequency of CD4+ T cells in recipients of
PBSC grafts that produced IL-2, IFN-γ, or TNF-α in response
to incubation with a HCMV lysate also did not find a deficiency
in these cell responses compared to BM recipients (Waller et al.,
2019). In fact, these recipients of PBSC grafts had faster T cell
reconstitution, including more naïve CD4+ T cells. Therefore,
more studies are required to determine if the apparent increased
risk of HCMV reactivation with G-CSF use warrants a more
cautionary use of this product.
Investigations of the recovery of CMV specific CD4+ T cells
in HSCT patients demonstrated that there are different kinetic
patterns that result in the recovery of the CD4+ T cell response:
(i) rapid expansion of IFN-γ secreting T cells within the first
week after initiation of pre-emptive therapy concomitant with
rapid clearance, (ii) early expansion of a lower magnitude than
that seen in rapidly cleared episodes, and (iii) an inconsistent
or lack of expansion associated with persistent CMV DNAemia
(Tormo et al., 2010b). The reconstitution of HCMV-specific
CD4+ T cells can also be stratified by donor and recipient
serostatus—recovery is fastest in D+/R+, followed by D–/R+,
and is slowest in D+/R– populations (Lilleri et al., 2008a).
In fact, in D+/R+ patients, it appears that the reconstitution
kinetics of HCMV-specific CD4+ T cells are the same as HCMV-
specific CD8+ T cells (Foster et al., 2002). It is important
when interpreting these results to remember that reconstitution
of CMV specific CD4+ T cells is not equivalent to recovery
of a fully functional CMV specific CD4+ T cell response.
Measuring whether there is a lymphoproliferative response to
CMV antigens is possibly more reflective of the actual ability
of the T cells to prevent HCMV reactivation and disease. Early
studies in allogeneic bone marrow transplant patients showed
that up to 30% of recipients with a lack of a CMV-specific
CD4+ lymphoproliferative responses by day 120 post-transplant
develop CMVdisease (Krause et al., 1997).WhenHCMV-specific
CD4+ T cells in pediatric allogeneic HSCT recipients were
examined for both IFN-γ and proliferative responses, there was
first a recovery of the IFN-γ response before the proliferative
response (Guerin et al., 2010). This is also seen in primary
HCMV infection, where development of the lymphoproliferative
response to HCMV is delayed compared to the development of
CD4+ and CD8+ IFN-γ-producing T cells (Fornara et al., 2016).
Surface Markers of HCMV-Specific CD4+ T Cells in
HSCT Recipients
Alongside measuring HCMV T-cell reconstitution in HSCT
recipients, some studies have assessed whether HCMV-specific
CD4+ T cells which are polyfunctional, measured by an ability
to produce both IFN-γ and IL-2 in response to HCMV, are
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more likely to be protected from HCMV reactivation (Lilleri
et al., 2008a). IL-2 is a cytokine which can have multiple effects
on CD4+ T cell immune responses, including modulating the
development of T cells into memory subsets. It signals to the
T cell via binding to the IL-2 receptor, a complex consisting of
three chains, termed α (CD25), β (CD122), and γ (CD132) (Liao
et al., 2011). Increased risk of HCMV reactivation is associated
with reduced numbers of CD4+CD25high cells, and a study
of 99 HSCT recipients found that numbers of CD4+CD25high
but not CD4+ T cells was an independent factor for risk
of CMV reactivation (Jaskula et al., 2015). The expression of
other functional markers on HCMV specific CD4+ T cells
have also been studied in HSCT and SOT patients. Patients
with PCR-positive reactivations after HSCT were found to have
more frequent occurrences of CD4+ T cells with degranulation
markers CD107a and co-stimulatory molecule CD40L (Krol
et al., 2011). The frequencies of appearance of these markers
corresponded with a higher antigen load. This subpopulation
of CD4+ T cells was previously described to be MHC class II-
restricted cytotoxic T cells in primary disease in SOT patients
(Gamadia et al., 2004; van Leeuwen et al., 2004; van de Berg
et al., 2008). The typical phenotype of CMV specific CD4+ T
cells in healthy people has been described in the introduction
of this review and include the loss of co-stimulatory molecules
CD28 andCD27. This phenotype is also observed in SOT patients
(van Leeuwen et al., 2004, 2006; Dirks et al., 2013; Burton et al.,
2018, 2019) and is now used to predict CMV infection history
in transplant patients where the use of serology is unreliable
(Burton et al., 2018, 2019). The loss of PD-1 is also observed in
these patients (Dirks et al., 2013). These HCMV-specific CD4+
T cells tended to show impaired production of IL-2 for first 6
months following HSCT, but the ratio of IL-2/IFN-γ production
then increases with time post-transplant (Pourgheysari et al.,
2009), suggesting a conversion from an effector memory to a
central memory phenotype. HCMV reactivation has also been
demonstrated to cause a contraction of the TCRβ diversity.
An investigation of the CD4+ T naïve population from 7
HSCT recipients that had HCMV reactivation showed that these
patients had a progressive loss of CD31+CD4+ Tnaïve cells.
CD31+CD4+ T cells are enriched in new thymic emigrants,
and a loss of this population suggests that there is thymic
compromise in patients that reactivate HCMV (Suessmuth et al.,
2015). HCMV reactivation was also associated with significant
expansion of CD8+ T cells, resulting in an inversion of the
CD4:CD8 ratio in HCMV reactivating patients (Suessmuth et al.,
2015). The authors cited previous studies which show that
HCMV can infect thymic epithelium and activated and effector
T cells can directly infiltrate and damage the thymus (Mocarski
et al., 1993).
CD4+ T Cells and Adoptive Transfer
Therapies for HCMV Disease in Transplant
Patients
Since the initial trial of donor T cell infusion in 1995 (Walter
et al., 1995), multiple phase 1 and 2 clinical trials of adoptive
T cell therapies in HSCT recipients have been performed
(reviewed in Meesing and Razonable, 2018; van der Heiden
et al., 2018a; Girmenia et al., 2019). In SOT recipients, the
challenge of autologous adoptive T cell therapy is to be able to
generate a sufficient number of CMV-specific T cells from the
immunosuppressed recipients. Multiple case reports performed
in mostly lung transplant recipients appear to have shown
potential (Brestrich et al., 2009; Holmes-Liew et al., 2015; Pierucci
et al., 2016), though there has been just one clinical trial of
autologous CMV-specific T-cell therapy in SOT recipients so far
(Smith et al., 2018).
In the initial published trial of adoptive immunotherapy
(Walter et al., 1995), clones of CMV-specific CD8+ cytotoxic
T cells were infused into 14 allogeneic bone marrow transplant
recipients. There was reconstitution of CMV-specific T cell
cytotoxicity in all patients, but this activity subsequently declined
in patients that were deficient in CMV-specific CD4+ T cells,
suggesting that CD4+ T cells were crucial in the maintenance
of the CMV-specific T cell response. There was a change
of approach in subsequent trials of adoptive immunotherapy,
and preparation of the T-cell infusions involved pulsing donor
dendritic cells with CMV antigen, then co-culturing with PBMCs
and subsequently selecting for CMV-specific T cells, resulting
in infusions containing CD8+ and CD4+ CMV-specific T cells.
Though not all the trials evaluated if the infusions consisted
of more CD8+ or CD4+ T cells, in those that did, there
appears to be a predominance of CD4+ T cells. As the use of
adoptive immunotherapy was pursued, subsequent clinical trials
modified the protocol to stimulate mononuclear cells isolated
from peripheral blood of the donors up to 4 times with CMV
antigen, and the resultant proliferation of CMV-specific T cells
was mostly CD4+ dominant. Following infusion, clinically there
was clearance of viremia in 5 out of 7 patients, although it should
be noted that these patients had only low to moderate levels of
viremia (Einsele et al., 2002). This is supported by a few later
studies (Leibold et al., 2012; Albiero et al., 2016) that looked
at the CD4+/CD8+ ratio within T-cell lines isolated for IFN-γ
production in response to pp65 stimulation—in one study, up
to 90% of the T cells were found to be CD4+ (Leibold et al.,
2012). The CMV specific CD4+ T cells that are infused perform
better when they replicate the phenotype and functionality
of effective CD4+ T cell responses against CMV disease in
transplant patients. More recently the functional and phenotypic
characteristics of HCMV peptide pool-generated antigen-specific
CD4+ T cells used for CMV T cell therapy has been assessed
(Hammoud et al., 2013). This study proposes that it is important
to generate polyfunctional CMV specific CD4+ T cells that are
both directly anti-viral but can also support CMV specific CD8+
T cell responses to improve the efficacy of adoptive CMV specific
T cell therapy in patients. In the majority of these T cell therapy
trials, the CMV antigens used to generate the CMV-specific T cell
lines were derived from the tegument protein pp65. Interestingly,
one study compared using pp65 vs. IE1 antigens as stimulant
(Albiero et al., 2016), and found that there was a much higher
degree of expansion with IE1 (1- to 961-fold) than pp65 (1-to 33-
fold), and that there was a greater expansion of CD4+ T cells
exhibiting a Tnaïve stem cell phenotype (CD62L+CD45RA+) on
stimulation with IE1 as compared to pp65. This demonstrates
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that when developing adoptive T cell therapy for CMV disease it
is important to consider generating polyfunctional CD4+ T cells
specific to multiple CMV antigens.
Of recent interest has also been the use of stored CMV-specific
T cells from third-party donors for T cell therapy. This involves
generating virus-specific T cell lines (VST) from pre-selected
donors and expanding these VSTs ex vivo. These T cells are then
cryopreserved, and, when needed for patients with refractory
viremia, a VST from a HLA-matched donor can be used “off-the-
shelf.” The advantage of such an approach over using VSTs from
a specific donor is that it eliminates the usual 2–3 week waiting
period needed to generate a VST. A multi-center trial involving
23 patients with refractory CMV infection showed that 17 of
these patients responded to VST infusion, although the authors
of this study could not identify a correlation between CD4+ T
cell numbers or percentage in the infused line with the strength
of clinical response (Leen et al., 2013). A later study involving 30
allogeneic HSCT recipients with persistent or recurrent HCMV,
EBV or adenovirus infections tracked the subpopulations of T-
lymphocytes in these patients up to 1 year post-infusion, and
found that within the CD4+ T cell memory subset, effector
memory T cells were dominant throughout follow-up (Withers
et al., 2017). The percentage of CD4+ T cells in these infusions
ranged from 15 to 85%, but the authors made no comment
on an association of CD4+ T cell proportion with successful
treatment. A third study consisted of 8 HSCT recipients who
received third party donor infusions of HCMV-specific CD8+
T cells. In this study it was thought that HCMV-specific CD4+
T cells were not essential for the activity of these CD8+ T cells.
However, 3 of the 8 patients died, and only one treated donor
successfully expanded the transferred CD8+ T cell population
(Neuenhahn et al., 2017). Thus, more studies are required to
determine if HCMV-specific CD4+ T cells are essential for
successful treatment of persistent or recurrent HCMV disease by
third party donor lymphocyte infusions.
CD4+ T Cells and Congenital HCMV
The risk of transmission of CMV from mother to fetus, resulting
in congenital CMV infection, is highest in primary infection in
the mother, with reported ranges of approximately 40% (Fowler
et al., 1992). However, transmission of CMV to the fetus can
also occur in mothers who are seropositive, albeit at much lower
rates (Kenneson and Cannon, 2007; Britt, 2015). These were
initially thought to occur as a result of reactivation of latent virus,
although more recent studies have suggested that infection with
a serologically distinct strain of HCMV may be a cause as well
(Ross et al., 2010; Yamamoto et al., 2010).
The kinetics of the development of an antibody response
during primary HCMV infection in pregnant vs. non-pregnant
women appear to be comparable (Revello et al., 2006), but
pregnant women having a primary infection appear to have a
decreased CD4+ lymphoproliferative response to CMV lysate
and IL-2 production for at least 9 months after infection (Fornara
et al., 2011). Mothers that do not transmit CMV to the fetus
are more likely to have an earlier and higher lymphoproliferative
response of CD4+ T cells to HCMV (Revello et al., 2006; Fornara
et al., 2016), with some observations that the CD4+ response
develops earlier than the CD8+ lymphoproliferative response
(Lilleri et al., 2007a). The CMV-specific CD4+ T cells of these
non-transmitting mothers also had higher percentages of IL-
7Rpos (Mele et al., 2017), CD45RA+ (Fornara et al., 2011,
2016), and IL-2 (Fornara et al., 2016). When compared with
healthy sero-negative pregnant mothers, the CD4+ T cells of
sero-positive pregnant women had higher levels of IFN-γ and
TNF-α production in response to exposure to CMV antigen, but
this response was less than in healthy, non-pregnant seropositive
females (Fujikawa et al., 2003). In fact, an examination of 44
pregnant women with primary HCMV infection showed that
most of these IFN-γ-producing T cells were CD4+ (Fornara
et al., 2017).
Decreased cytokine production following stimulation with
CMV antigens is also seen in infants with congenital CMV. An
analysis of seven infants with congenital CMV infection showed
a lack of production of IFN-γ, IL-2, and IL-4 from CD4+ T cells
on exposure to pp65-derived peptide (Hayashi et al., 2003). Other
early studies made the observation that symptomatic children
with congenital CMV had higher percentages of CD4+ T cells
that produced IFN-γ and TNF-α in response to CMV antigen,
though there was a limitation of small sample sizes (Numazaki
et al., 2002; Fujikawa et al., 2003), and a later study of the response
of CD4+ T cells from congenitally infected infants showed they
had a reduced polyfunctional response (defined as ≥2 out of
CD107, MIP1β, IFN-γ, and/or IL-2) to pp65 antigen (Gibson
et al., 2015).
A comparison of congenitally infected neonates and their
mothers showed that neonatal sera contained significantly higher
levels of IL-8 when compared with their mothers, and also had
increased levels of IL-2, IL-12, and IFN-γ with a corresponding
lack of IL-4, suggesting a predominantly T helper 1 response
(Hassan et al., 2007). There may also be extrapolations that
can be made from studies of HIV-positive mothers co-infected
with HCMV. A maternal CD4+ T cell count of <200 cells/ul is
associated with higher risk of transmission to the fetus (Gantt
et al., 2016). Retrospective studies of infants born to HIV-
positive mothers showed that, if their mothers received full anti-
retroviral prophylaxis, they had higher CD4+ T cell counts
(Mania et al., 2013) and were less likely to have congenital CMV
(Guibert et al., 2009).
A large Swedish study of infants up to 2 years of age with
congenital CMV infection found that they had CMV-specific
CD4+ T cell responses (measured by IFN-γ) that were inferior
compared to adults during the first 3 months of age, though this
difference was not significant by the age of 24 months (Lidehall
et al., 2013). This was in contrast to the CD4+ T cell responses
in 8 adults with primary CMV infection, which was high initially
and then subsequently decreased. This increase in CMV-specific
CD4+ T cells appears to be approximately linear (Chen et al.,
2016). The slower increase of CD4+ T cell function may explain
the longer duration of viral shedding seen in neonates and
children (Tu et al., 2004; Cannon et al., 2011), and illustrates the
important role CD4+ T cells play in controlling CMV disease. In
addition to causing a slower increase of fetal CD4+ T cells, CMV
infection in utero also appears to cause an oligoclonal expansion
of CD4+ T cells in the infected newborn. Higher frequencies
of CD27-CD28-CD4+ T cells were detected in newborns with
congenital CMV, with decreased expression of CCR7, IL-7R
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and increased expression of CD57 and the transcription factor
T-bet and chemokine receptor CCR5, indicating Th1 and Tc1
phenotypes. They also had a higher expression of the PD-1
inhibitory receptor, a similar profile to that seen in exhausted T
lymphocytes (Huygens et al., 2015).
The importance of CD4+ T cells to generate a sustained
and protective response to CMV is also seen in vaccine studies.
In the rhesus model of CMV, rhesus macaques that received
CD4+ T-cell-depleting antibody had fetal loss or infant rhCMV-
associated sequelae (Bialas et al., 2015). A phase 2 clinical trial
for a gB-based vaccine with MF59 adjuvant showed an efficacy of
50% (Pass et al., 2009), and subsequent analysis of the immune
response showed that there was not only an increase in antibody
production but there also an increase in gB-specific CD4+ T
cell proliferation and IFN-γ production after vaccination (Sabbaj
et al., 2011), suggesting that, just like in primary infection
(Gamadia et al., 2003), the formation of effector memory CD4+
T cells was needed for an effective and sustained immune
response to CMV.
CD4+ T Cell Lessons From Murine Models
Whilst the many human studies described in this review have
illustrated the essential role CD4+ T cells play in resolving CMV
disease, there are limitations to these studies. The use of mouse
models can help to inform our understanding of the mechanisms
and function of CD4+ T cells in CMV disease. During acute
MCMV infection in mice, the CD4+ T cell response peaks early
and then contracts sharply to very low levels, and is dominated by
high frequencies of IFN-γ and TNF-α double-producing CD4+
T cells (Arens et al., 2008; Walton et al., 2008). These MCMV-
specific CD4+ T cells accumulate in the spleen and lungs and
produce multiple cytokines—IFNγ, TNF, IL-2, IL-10, and IL-
17 (Arens et al., 2008). In the lungs of infected mice, nodular
inflammatory foci form around infected cells, which contain
CD8+ and CD4+ T cells and exert viral control via IFN-γ
and perforin (Lueder et al., 2018). However, in the context of
suppressing viral reactivation, CD4+ T cells are not as essential,
as experiments in a B-cell deficient mouse model have established
a hierarchy of CD8+ T cells being more crucial to suppressing
viral reactivation compared to CD4+ T cells (Polic et al., 1998),
with viral control and expansion of these MCMV-specific CD4+
T cells being dependent on CD27-CD70 co-stimulation (Welten
et al., 2013). There is also evidence for cytolytic activity of CD4+
T cells in MCMV model. MCMV-specific CD4+ T cells that had
high levels of granzyme B expression were able to lyse infected
target cells in the BALB/c mouse liver. In addition, CD4+ T cell
epitope vaccination of immunocompetent mice reduced MCMV
replication in the same organs where this cytotoxic activity was
seen (Verma et al., 2015).
Approaches to Examining the Role of CD4+ T Cells in
MCMV Infection
There have been multiple approaches to interrogating the
role of CD4+ T cells in the control of MCMV infection.
The first approach involves depletion of CD4+ T cells. This
was initially achieved through injecting mice with anti-CD4+
(L3T4) antibodies. Early studies using anti-CD4+ monoclonal
antibodies to deplete CD4+ T cells showed that these BALB/c
strain of mice had delayed clearance of replicating virus, but were
still able to generate protective CD8+ effector T cells and restrict
viral replication to the acinar cells of the salivary glands (Jonjic
et al., 1989). This finding was repeated in a later experiment
using a different mouse strain, C57BL/6, where mice depleted of
CD4+ T cells were unable to control chronic viral replication in
the liver and salivary glands (Walton et al., 2008). Subsequently,
it was demonstrated that MHC class I and II expression was
detectable only at low levels in salivary gland cells and that
antigen-presenting cells in the salivary gland were deficient in
cross-presentation to CD8+ T cells, thus control of MCMV
replication in the salivary gland was likely to be due to CD4+
T cells that had been selectively induced by antigen-presenting
cells in the salivary glands (Walton et al., 2011a). These MCMV-
specific CD4+ T cells produce IL-10, which in turn is induced by
IL-27, and these cytokines promote persistence of MCMV in the
salivary glands (Humphreys et al., 2007; Wehrens et al., 2018).
Another approach involved generating knockout mouse
models—CD4−/− and MHC II−/−. One major difference
between these two lines is that CD4−/− mice are able to generate
isotype-switched antibody responses. This is achieved via a
population of CD8- CD4- T cells that are capable of adopting
some of the function of Thelper cells, such as mediating antibody
class switching (Locksley et al., 1993; Rahemtulla et al., 1994) and
supporting somatic hyper-mutation and affinity maturation of
germinal center B cells (Zheng et al., 2002). There also exists a
population of MHCII-restricted T cells that are misdirected into
the CD8 lineage (Matechak et al., 1996; Tyznik et al., 2004). In
contrast to the mice depleted with anti-CD4+ T cell antibodies,
when CD4−/− mice were infected with MCMV, these mice were
able to clear viral infection in all organs, albeit at a slower rate (of
200 to 400 days post-infection) than wildtype controls (Walton
et al., 2011a). A possible reason for this difference is that the
viral loads in the organs of the CD4−/− mice were observed
for much longer periods than the earlier studies. When MHC
II−/− mice were infected with MCMV, they were not able to
eliminate viral replication. As MCMV-specific antibodies were
previously shown to inhibit viral dissemination during MCMV
infection, the authors surmised that the inability to generate
isotype-switched antibody responses was the likely reason that
CD4−/− but not MHC II−/− mice were able to halt active
MCMV replication (Jonjic et al., 1994; Wirtz et al., 2008).
It thus appears that CD4+ T cells are not essential to
elimination of actively replicating MCMV. To examine if CD4+
T cells provide assistance to CD8+ T cells in clearance of
replicating virus, CD4−/− mice were infected with MCMV,
and the percentage of CD8+ T cells that recognized various
MCMV epitopes were measured at multiple time points post-
infection. The results showed that only accumulation of the late-
appearing IE3-specific CD8+ T cells was substantially impaired,
suggesting that the help that CD4+ T cells provide to CD8+ T
cells is limited to assisting in the expansion of only a limited
subset of MCMV-specific CD8+ T cells (Snyder et al., 2009).
A caveat of interpreting this result was that only very limited
epitopes (M45, M38, m139, and IE3) were tested, and with the
knowledge that a large repertoire of epitopes are recognized
Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 11 May 2020 | Volume 10 | Article 202
Lim et al. CD4+ T Cell Response to HCMV
by T cells, perhaps more extensive testing needs to occur.
The CD4+ T cell help provided via MHC II expression is
also needed to maintain a stable CD8+ T cell memory pool,
although ongoing lytic viral replication is partially able to
provide this assistance as well. When splenic CD8+ T cells
from CD4-deficient MHC II−/− mice that had been chronically
infected with MCMV were transferred into mice that were then
infected with MCMV, the CD8+ T cells from MHC II−/−
mice proliferated much less vigorously than CD8+ T cells from
wildtype mice (Walton et al., 2011b).
A third approach involves using adoptive transfer techniques,
which can help to inform the equivalent adoptive transfer T
cell therapies employed in transplant patients. Early studies
of transfer of CD4+ T cells into irradiated Balb/c mice that
were subsequently infected with MCMV showed that CD4+
T cells were not able to prevent viral replication in the
lungs (Reddehase et al., 1985, 1987), spleen or adrenal glands
(Reddehase et al., 1988). Later studies using the same murine
system also demonstrated that controlling CMV mediated lung
disease in treated mice required CD8+ T cells rather than CD4+
T cells (Steffens et al., 1998; Podlech et al., 2000). However,
when adoptive transfer was performed in severe combined
immunodeficiency (SCID) mice, CD4+ T cells were able to
prevent viral dissemination in the brain (Reuter et al., 2005).
Overall, therefore, CD4+ T cells appear to be essential only
for control of viral replication in the specific organs in the
mouse model.
Caveats to Interpreting MCMV Models
Limitations exist in extrapolating the findings in murine models
of cytomegalovirus infection, due to the underlying differences
between murine CMV infection and HCMV (Lemmermann
and Reddehase, 2016). In an early mouse model of adoptive
immunotherapy, transfer of CD4+ T cells into irradiated and
MCMV-infected mice did not reduce viral titers in the lungs,
spleen nor adrenal glands of these mice. In contrast, transfer of
CD8+ T cells had significant reductions in viral titers (Reddehase
et al., 1988). When graded numbers of CD4+ T cells were
transferred with a constant number of CD8+ T cells, there was
no difference to viral titers either (suggesting no helper effect).
However, as already discussed it is clear that in the case of HCMV
infection CD4+ T cells are a necessary component of CMV T
cell therapy.
There have thus been attempts to create a “humanized” mouse
model of CMV infection, by generating an immune deficient
mouse with a mutation in IL-2 receptor γ-chain locus (IL-
2γc −/−) that is severely impaired in generating mouse B, T
and NK cell lines (reviewed in Shultz et al., 2012; Crawford
et al., 2015). When these mice were engrafted with human
haematopoietic progenitor cells, they were able to reconstitute
monocytes, macrophages and limited T-cells. This model was
further refined by reconstituting these mice with human fetal
bone marrow, liver and thymus tissue (Covassin et al., 2013).
Latent infection of these mice were able to induce generation of
central and effector memory HCMV-specific T-cells and produce
HCMV-specific IgM and IgG neutralizing antibodies (Crawford
et al., 2017). Adoptive transfer of CD4+ T cells in such a model
has shown that these CD4+ T cells did not have an anti-viral
effect on their own, but when co-administered with CD8+ T
cells, they appeared to enhance the anti-viral efficacy of CD8+
T cells and significantly decreased viral titers in the spleen and
lungs (Thomas et al., 2015).
CONCLUSIONS
It is clear that there is increasing evidence to show that CD4+
T cells play a significant role in anti-viral immunity to HCMV.
The virus has evolved immune evasion mechanisms to target
the MHC class II antigen presentation pathway, the method by
which CD4+ T cells TCR recognize presented viral peptides
triggering cell activation and anti-viral functions. Following
primary infection, there is development of a CMV-specific CD4+
T cell population that persists in the T cell repertoire of healthy
adults, suggesting that this population of T cells is required for
a healthy immune response to control periodic episodes of viral
reactivation over a life time of the infected host. In both SOT and
HSCT recipients, the presence of CMV-specific CD4+ T cells are
highly associated with lower risks of developing CMV disease
by reactivation of latent virus, and conversely, the lack of this
population of T cells herald a higher likelihood of developing
recurrent CMV viremia and end-organ disease.
However, many questions still remain unanswered. The
majority of studies referenced in this review show an association
of the presence of CMV-specific CD4+ T cells with protection
from disease, but few have attempted to explain the mechanism
of how this occurs. Attempts to interrogate how they exert
their effects have mostly been limited to demonstrating presence
of cytokines and activation markers on these CD4+ T cells
as a response to exposure to CMV antigens. More work has
been done in the murine model on attempting to elucidate this
mechanism by generating various knockout mouse models, but
interpretations from these models are limited by the apparent
greater dispensability of CD4+ T cells in control of MCMV
disease. As such, more work needs to be done to investigate
this, with the possibility of using this knowledge to further
refine techniques for adoptive therapies or vaccine studies. In
addition, it is also clear that current techniques of measuring
CD4+ T cell responses do not provide a complete picture of
the contribution of CD4+ T cells to the immunological response
to CMV. Methods that assess effector function more accurately,
such as anti-viral assays, may provide a more nuanced prediction
of developing CMV-related disease, and allow clinicians to tailor
anti-viral therapies better.
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